Cagrilintide
Long-acting amylin analogue that provides powerful appetite control through a completely different receptor pathway than GLP-1s.
Category
Weight Loss (Amylin Analogue)
Frequency
Once weekly injection
Research
Phase 3 Clinical TrialsWhat is Cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide hormone co-secreted with insulin by pancreatic beta cells after meals. Amylin normally signals satiety to the brain and slows gastric emptying — Cagrilintide amplifies and extends these effects dramatically.
Developed by Novo Nordisk, Cagrilintide is being studied both as a standalone weight loss agent and in combination with Semaglutide (as "CagriSema"). In Phase 2 trials, Cagrilintide alone produced ~10.8% weight loss over 26 weeks. When combined with Semaglutide 2.4mg, the CagriSema combination produced approximately 15.6% weight loss — suggesting significant synergy.
The key advantage of Cagrilintide is that it works through amylin receptors rather than GLP-1 receptors, making it an excellent stack partner with GLP-1 agonists. Its mechanism produces a different pattern of satiety — users report feeling less focused on food throughout the day rather than nausea-driven appetite loss.
How It Works
Amylin Receptor Agonism: Activates amylin receptors in the area postrema and nucleus tractus solitarius of the brain — regions involved in satiety signaling and nausea regulation. This differs from GLP-1 receptor locations.
Gastric Emptying: Slows the rate at which food leaves the stomach, extending the feeling of fullness after meals and blunting postprandial glucose spikes.
Glucagon Suppression: Like amylin, Cagrilintide suppresses postprandial glucagon release, which reduces liver glucose output and improves overall metabolic control.
Central Appetite Regulation: Acts directly on appetite-regulating centers in the hypothalamus to reduce caloric intake without requiring the same magnitude of nausea as GLP-1s at equivalent appetite-suppressing doses.
Benefits
- ~10.8% weight loss as monotherapy in Phase 2 trials
- Synergistic with GLP-1 peptides (CagriSema combo shows 15.6%+ loss)
- Different mechanism to GLP-1 — can stack effectively
- Powerful appetite control through amylin pathway
- Weekly dosing for convenience
- Potentially less nausea than GLP-1s at equivalent satiety levels
- Improves postprandial glucose control
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 0.16mg | Once weekly | Weeks 1–4 |
| Titration 1 | 0.3mg | Once weekly | Weeks 5–8 |
| Titration 2 | 0.6mg | Once weekly | Weeks 9–16 |
| Target | 1.2–2.4mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Nausea (common during titration)
- ⚠Decreased appetite
- ⚠Vomiting (resolves with slower titration)
- ⚠Diarrhea or constipation
- ⚠Injection site reactions
Rare
- •Hypoglycemia (especially if combined with insulin)
- •Pancreatitis risk (theoretical)
- •Gallbladder issues (associated with rapid weight loss)
Who Should NOT Use Cagrilintide
- ✕Type 1 diabetes (amylin analogue specific concern)
- ✕History of pancreatitis
- ✕Gastroparesis or severe GI motility disorders
- ✕Pregnancy or breastfeeding
- ✕Under 18 years old
- ✕Severe renal impairment
What to Expect
Titration phase at 0.16mg. Mild appetite reduction begins. Some nausea during dose adjustment is expected.
At 0.3mg, appetite suppression becomes more pronounced. Food intake naturally decreases. First meaningful weight loss.
At target dose, consistent weekly weight loss. Appetite control feels different from GLP-1s — less acute nausea, more background satiety.
FAQ
Q: Should I stack Cagrilintide with a GLP-1 peptide?
A: The CagriSema combination (Cagrilintide + Semaglutide) showed excellent Phase 3 results. Stacking with Semaglutide or Tirzepatide is popular but doses should be kept conservative when combining. Start with lower doses of both and titrate carefully.
Q: How does Cagrilintide compare to Retatrutide?
A: Retatrutide as a standalone produces more weight loss (~28.7% vs ~10.8%). However, Cagrilintide + Semaglutide approaches Retatrutide's results. Cagrilintide's main advantage is its complementary mechanism for stacking.
Q: Where can I source Cagrilintide in Vietnam?
A: Cagrilintide is less commonly stocked than Retatrutide or Tirzepatide in Vietnam. Check the Supply Index for current availability from verified suppliers.
Where to Get Cagrilintide in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
View Supply Index